Clinical trial · Interventional
Comparative Study of Different Doses of Magnesium as a Protective Agent in Nephrotoxicity in Cancer Patients
Comparative Study of Different Doses of Magnesium as a Protective Agent in Cisplatin Induced Nephrotoxicity in Patients With Head and Neck Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this \[ type of study: intervential study is to compare between different doses of magnesium to prevent cisplatin induced nephrotoxicity.\] In 75 participant population with head and neck cancer recieved cisplatin it aims to answer are: • • optimal doses of magnesium as 3 groups each group take 1gm of magnesium then second group take 2gm of magnesium and finally third group take 3gm of magnesium Researchers will compare \[ 3 groups \] to see if \[ magnesium has effects in prevention cisplatin nephrotoxicity\].
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cisplatin Adverse Reaction | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cisplatin 40 mg/m² | Drug | Cisplatin | ALIAS |
| cisplatin with hydration magnesium | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- ACTIVE_COMPARATOR
- label
- Group 1
- description
- (n=25): receive cisplatin with hydration 1000mg magnesium (8 q) intravenous infusion ( IVI ).
- interventionNames
- Drug: cisplatin with hydration magnesium
- type
- ACTIVE_COMPARATOR
- label
- Group 2
- description
- (n=25): receive cisplatin with hydration 2000mg magnesium (16 Meq) ( IVI ).
- interventionNames
- Drug: cisplatin with hydration magnesium
- type
- ACTIVE_COMPARATOR
- label
- Group 3
- description
- (n=25): receive cisplatin with hydration 3000 mg magnesium (32 Meq) ( IVI ).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * diagnosed with head and neck cancer recieved cisplatin ECOG \<2 eGFR\>59 ml/min/1.73 Adequate hematological parameters Exclusion Criteria: * pregnant and lactating women Using of nephrotoxic drugs as NSAIDs Patients with hypersensitivity to any drug used Diabetic patients Patients with cardiovascular diseases
References
Publications (0)
Data not yet available